BE903541Q - Procede de fabrication d'un latex coagule de configuration spherique - Google Patents

Procede de fabrication d'un latex coagule de configuration spherique

Info

Publication number
BE903541Q
BE903541Q BE0/215789A BE215789A BE903541Q BE 903541 Q BE903541 Q BE 903541Q BE 0/215789 A BE0/215789 A BE 0/215789A BE 215789 A BE215789 A BE 215789A BE 903541 Q BE903541 Q BE 903541Q
Authority
BE
Belgium
Prior art keywords
latex
coagule
manufacturing
spherical configuration
coagulated
Prior art date
Application number
BE0/215789A
Other languages
English (en)
French (fr)
Original Assignee
Kanegafuchi Chemical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanegafuchi Chemical Ind filed Critical Kanegafuchi Chemical Ind
Application granted granted Critical
Publication of BE903541Q publication Critical patent/BE903541Q/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/18—Chewing gum characterised by shape, structure or physical form, e.g. aerated products
    • A23G4/20—Composite products, e.g. centre-filled, multi-layer, laminated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
BE0/215789A 1984-10-30 1985-10-29 Procede de fabrication d'un latex coagule de configuration spherique BE903541Q (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE278884A IE58110B1 (en) 1984-10-30 1984-10-30 Controlled release powder and process for its preparation

Publications (1)

Publication Number Publication Date
BE903541Q true BE903541Q (fr) 1986-02-17

Family

ID=11036490

Family Applications (2)

Application Number Title Priority Date Filing Date
BE0/215789A BE903541Q (fr) 1984-10-30 1985-10-29 Procede de fabrication d'un latex coagule de configuration spherique
BE0/215788A BE903540A (fr) 1984-10-30 1985-10-29 Formulations a liberation progressive, procede pour leur preparation et compositions les renfermant

Family Applications After (1)

Application Number Title Priority Date Filing Date
BE0/215788A BE903540A (fr) 1984-10-30 1985-10-29 Formulations a liberation progressive, procede pour leur preparation et compositions les renfermant

Country Status (16)

Country Link
US (3) US4940588A (enExample)
JP (1) JP2820239B2 (enExample)
AU (1) AU579415B2 (enExample)
BE (2) BE903541Q (enExample)
CA (1) CA1268051A (enExample)
CH (1) CH669728A5 (enExample)
DE (1) DE3538429C2 (enExample)
DK (1) DK175329B1 (enExample)
FR (1) FR2572282B1 (enExample)
GB (1) GB2166651B (enExample)
HK (1) HK44091A (enExample)
IE (1) IE58110B1 (enExample)
IT (1) IT1185831B (enExample)
NL (1) NL193582C (enExample)
SE (1) SE8505099L (enExample)
ZA (1) ZA858300B (enExample)

Families Citing this family (1369)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
CH669523A5 (enExample) * 1986-06-25 1989-03-31 Mepha Ag
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5030632A (en) * 1986-09-23 1991-07-09 Sandoz Pharm. Corp. Low dose temazepam
US5629310A (en) * 1986-09-23 1997-05-13 Sterling; William R. Low dose temazepam
US5211954A (en) * 1986-09-23 1993-05-18 Sandoz Ltd. Low dose temazepam
GB8624628D0 (en) * 1986-10-14 1986-11-19 Scras Soluble/splitable tablets
HU205861B (en) * 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
SE8605515D0 (sv) * 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a pharmaceutically active substance
CH673395A5 (enExample) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US4975270A (en) * 1987-04-21 1990-12-04 Nabisco Brands, Inc. Elastomer encased active ingredients
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
EP0297866A3 (en) * 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
NZ226822A (en) * 1987-11-16 1990-03-27 Mcneil Consumer Prod Chewable medicament tablet containing means for taste masking
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
ZA892859B (en) * 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
DE3834944A1 (de) * 1988-10-13 1990-04-26 Ars Japan Kk Arzneimittelfreigabevorrichtung
US5840293A (en) * 1988-11-16 1998-11-24 Advanced Polymer Systems, Inc. Ionic beads for controlled release and adsorption
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5139787A (en) * 1989-01-19 1992-08-18 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5209923A (en) * 1989-05-30 1993-05-11 Moleculon, Inc. Sunscreen composition
US5223267A (en) * 1989-05-30 1993-06-29 Purepac, Inc. Analgesic compositions
US5206019A (en) * 1989-05-30 1993-04-27 Moleculon, Inc. Soap compositions containing liquid-loaded powders
US5290570A (en) * 1989-05-30 1994-03-01 Purepac, Inc. Lotions containing liquid-loaded powder
US5206022A (en) * 1989-05-30 1993-04-27 Moleculon, Inc. Insect repellent compositions
US5209932A (en) * 1989-05-30 1993-05-11 Moleculon, Inc. Foot care compositions
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
FR2649888B1 (fr) * 1989-07-18 1994-08-26 Exsymol Sa Produits pour applications cutanees, a effets cosmetiques ou/et therapeutiques
CA2063141C (en) * 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
NZ234587A (en) * 1989-08-04 1991-11-26 Mcneil Ppc Inc A chewable pharmaceutical tablet of compressed coated granules
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
ATE133856T1 (de) * 1989-11-06 1996-02-15 Alkermes Inc Herstellungsverfahren für proteinmikrosphären
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
EP0454044B1 (de) * 1990-04-25 1995-12-06 Hoechst Aktiengesellschaft Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff
FR2661683A1 (fr) * 1990-05-02 1991-11-08 Rhone Poulenc Chimie Systeme matriciel de liberation controlee comportant un principe actif hydrosoluble disperse dans une matrice constituee d'un copolymere silicone thermoplastique.
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
FR2669222B1 (fr) 1990-11-15 1995-03-03 Oreal Compositions cosmetiques sous forme de poudres coulees comprenant des microspheres creuses, et leur preparation.
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
US5562914A (en) * 1990-12-06 1996-10-08 Zeneca Inc. Impregnated porous granules and a polyurethane matrix held within the pores thereof and holding a liquid material for controlled release of liquid material and process therefor
GB9026682D0 (en) * 1990-12-07 1991-01-23 Walker Bryan J Lightweight aggregate
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5116627A (en) * 1991-03-07 1992-05-26 International Flavors & Fragrances Inc. Chewing gum containing compositions for controlled release of flavor bearing substances and process for producing same
US5629013A (en) * 1991-04-04 1997-05-13 The Procter & Gamble Company Chewable calcium carbonate antacid tablet compositions
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
ES2202302T3 (es) * 1991-05-28 2004-04-01 Mcneil-Ppc, Inc. Composicion masticable que libera un farmaco.
DE4120918A1 (de) * 1991-06-25 1993-01-07 Basf Ag Pulverfoermige praeparate aus einer wasserunloeslichen kernsubstanz und einer schutzhuelle
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
ES2034891B1 (es) * 1991-08-08 1993-12-16 Cusi Lab Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
US5300305A (en) * 1991-09-12 1994-04-05 The Procter & Gamble Company Breath protection microcapsules
FR2681248B1 (fr) * 1991-09-13 1995-04-28 Oreal Composition pour un traitement cosmetique et/ou pharmaceutique de longue duree des couches superieures de l'epiderme par une application topique sur la peau.
WO1993011754A1 (en) * 1991-12-11 1993-06-24 The Procter & Gamble Company Cetylpyridinium chloride and domiphen bromide in organic solvent
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2127877A1 (en) * 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
ZA932272B (en) * 1992-03-30 1993-10-19 Alza Corp Viscous suspensions of controlled-release drug particles
MX9301821A (es) * 1992-03-30 1994-03-31 Alza Corp Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
HU215958B (hu) * 1992-04-30 1999-03-29 Schering Corp. Eljárás stabil, hidratált, száraz ceftibuten porkészítmény előállítására perorális szuszpenziókhoz
EP0572731A1 (en) * 1992-06-01 1993-12-08 The Procter & Gamble Company Chewable preparation containing a decongestant
US5560921A (en) * 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Multi-core microspheres with delayed drug delivery and process for their manufacture.
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
EP0669128B1 (en) * 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5354553A (en) * 1992-12-08 1994-10-11 Church & Dwight Co., Inc Antiperspirant-deodorant cosmetic stick products
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CN1047075C (zh) * 1993-02-26 1999-12-08 普罗克特和甘保尔公司 比沙可啶剂型
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5415877A (en) * 1993-04-23 1995-05-16 Church & Dwight Co., Inc. Bicarbonate fungicide product with a combination of surfactant ingredients
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5520924A (en) * 1993-07-09 1996-05-28 Mizu Systems Corporation Methods and articles for administering drug to the oral cavity
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
GB2281861B (en) * 1993-09-21 1997-08-20 Johnson & Johnson Medical Bioabsorbable wound implant materials containing microspheres
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5516524A (en) * 1993-12-20 1996-05-14 The Procter & Gamble Company Laxative compositions containing bulk fiber
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US7077822B1 (en) * 1994-02-09 2006-07-18 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5938990A (en) * 1994-07-01 1999-08-17 Roche Vitamins Inc. Encapsulation of oleophilic substances and compositions produced thereby
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
NL9401703A (nl) * 1994-10-14 1996-05-01 Rijksuniversiteit Kauwgom.
US6555098B1 (en) 1994-12-09 2003-04-29 Church & Dwight Co., Inc. Cosmetic deodorant products containing encapsulated bicarbonate and fragrance ingredients
EP0717992A3 (en) * 1994-12-21 1998-03-25 McNEIL-PPC, INC. Aqueous suspension formulations for pharmaceutical applications
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
US6165988A (en) * 1995-02-10 2000-12-26 Christian Noe Medicament in particulate form
WO1996027288A1 (en) * 1995-03-08 1996-09-12 Church & Dwight Company, Inc. Encapsulated bicarbonate-containing agrochemical compositions
TW493991B (en) * 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
DE19516787A1 (de) * 1995-05-08 1996-11-14 Bayer Ag Gegen Gamma-Strahlung stabilisierte (Co)Polycarbonate
EP0862420A4 (en) * 1995-10-13 1999-11-03 Penn State Res Found SYNTHESIS OF DRUG SPRAY DRUG NANOPARTICLES
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
WO1997022249A1 (en) * 1995-12-21 1997-06-26 Basf Corporation Enhancing the rate of seed germination with application of ethylene biosynthesis inhibitors
CA2193714A1 (en) * 1995-12-21 1997-06-22 Wilhelm Rademacher Encapsulated plant growth regulator formulations and applications
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
AU751497B2 (en) * 1996-04-23 2002-08-15 Mayne Pharma International Pty Ltd Taste masked pharmaceutical compositions
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
FI990180A7 (fi) * 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
WO1998021961A1 (en) * 1996-11-22 1998-05-28 Rhone-Poulenc Agrochimie Novel solid compositions based on an insoluble cellulose derivative and a 1-arylpyrazole derivative
FR2764775A1 (fr) * 1997-06-20 1998-12-24 Rhone Poulenc Agrochimie Nouvelles compositions a base de 1-aryl-pyrazole
AU5225798A (en) * 1996-11-22 1998-06-10 Rhone-Poulenc Agrochimie Novel solid compositions with base of insoluble cellulose derivative and 1-aryl-pyrazole derivative
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
DE19726195A1 (de) 1997-06-20 1998-12-24 Bayer Ag Verwendung von Saccharin zur Stabilisierung von thermoplastischen, aromatischen Polycarbonaten
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999017742A2 (en) * 1997-10-03 1999-04-15 Elan Corporation, Plc Taste masked formulations
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
FI105074B (fi) * 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
KR20060067986A (ko) * 1998-06-15 2006-06-20 세프라코 아이엔시. 무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도
TR200003707T2 (tr) 1998-06-15 2001-06-21 Sepracor Inc. Apne , bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
ES2260916T3 (es) * 1998-07-08 2006-11-01 Kirin-Amgen, Inc. Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica.
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
GB9816724D0 (en) * 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6254891B1 (en) 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
WO2000016742A1 (en) * 1998-09-24 2000-03-30 The Procter & Gamble Company Chewable compositions containing dextromethorphan
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6902898B2 (en) * 1998-11-16 2005-06-07 National Institute Of Advanced Industrial Science And Technology Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
JP3141107B2 (ja) * 1998-11-16 2001-03-05 工業技術院長 ヒト由来ブラディオン蛋白質、それをコードするｄｎａ及びそれらの使用
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6261600B1 (en) 1999-04-30 2001-07-17 Drugtech Corporation Folic acid supplement
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20030083383A1 (en) * 1999-08-16 2003-05-01 Spallholz Julian E. Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
EP1671628B1 (en) 1999-09-03 2012-10-03 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
JP2003509439A (ja) * 1999-09-14 2003-03-11 スミスクライン・ビーチャム・コーポレイション 水性コーティングされたビーズレットの製法
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
US20020022627A1 (en) * 2000-03-31 2002-02-21 Dannenberg Andrew J. Inhibition of cyclooxygenase-2activity
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001261625B2 (en) 2000-05-16 2006-04-06 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
EP1296666A2 (en) * 2000-07-06 2003-04-02 Delsys Pharmaceutical Corporation Improved thyroid hormone formulations
JP2002037727A (ja) * 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
US7056533B2 (en) 2000-08-15 2006-06-06 Surmodics, Inc. Medicament incorporation matrix
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
CA2430669C (en) * 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
US6833377B2 (en) 2001-02-05 2004-12-21 Gevys Pharmaceuticals Ltd. Composition and method for potentiating drugs
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
EA011451B1 (ru) * 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
US7192612B2 (en) * 2001-02-22 2007-03-20 Purdue Research Foundation Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer
US6759064B2 (en) 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
CA2440016C (en) * 2001-03-23 2010-12-14 Gumlink A/S Coated degradable chewing gum with improved shelf life and process for preparing same
US20040156949A1 (en) * 2001-03-23 2004-08-12 Lone Andersen Degradable elastomers for chewing gum base
EP1370150B1 (en) * 2001-03-23 2007-11-21 Gumlink A/S One-step process for preparing chewing gum
ES2554389T3 (es) * 2001-03-23 2015-12-18 Gumlink A/S Goma de mascar biodegradable y método para manufacturar tal goma de mascar
WO2002076228A1 (en) * 2001-03-23 2002-10-03 Gumlink A/S Degradable resin substitute for chewing gum
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
AU2002346065A1 (en) * 2001-07-05 2003-01-21 Marantech Holding, Llc Methods of using electron active compounds for managing conditions afflicting mammals
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
EP1992335A1 (en) * 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
DE10163142A1 (de) 2001-12-20 2003-07-10 Henkel Kgaa Polymere Duftkapseln und ihre Herstellung
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
WO2003059319A1 (en) * 2002-01-14 2003-07-24 Dow Global Technologies Inc. Drug nanoparticles from template emulsions
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
IL163846A0 (en) 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US20040028729A1 (en) * 2002-04-29 2004-02-12 Shojaei Amir H. Pharmaceutical formulations with improved bioavailability
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
EP1556033A4 (en) * 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
DK1505973T3 (da) 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20060115433A1 (en) * 2002-07-02 2006-06-01 Andersen Rita B Compressed chewing gum
US20050175733A1 (en) * 2002-07-02 2005-08-11 Bitten Thorengaard Compressed resin moderated chewing gum
AU2002320959A1 (en) * 2002-07-02 2004-01-23 Gumlink As Compressed chewing gum tablet ii
US6673792B1 (en) 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
GB0216413D0 (en) * 2002-07-15 2002-08-21 Nestle Sa Tabletted chewing gum sweet
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
EP1542667B1 (en) 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
ES2578252T3 (es) * 2002-09-24 2016-07-22 Gumlink A/S Goma de mascar que comprende al menos dos polímeros biodegradables diferentes
CN1668206A (zh) * 2002-09-24 2005-09-14 古木林科有限公司 改进口香糖成分释放的口香糖
EP1542541B2 (en) * 2002-09-24 2016-09-07 Gumlink A/S Low moisture chewing gum
EP1542542B2 (en) * 2002-09-24 2013-09-04 Gumlink A/S Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer
AU2002342580B2 (en) * 2002-09-24 2008-05-15 Gumlink A/S Degradable chewing gum polymer
MXPA05003104A (es) 2002-09-25 2005-05-27 Euro Celtique Sa Hidromorfonas n-sustituidas y uso de las mismas.
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
EP1551386A4 (en) * 2002-09-27 2009-03-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR TREATING LUPUS WITH CLOFARABIN
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2499549C (en) * 2002-10-11 2012-01-24 Proteotech, Inc. Isolation, purification and synthesis of procyanidin b2 and uses thereof
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR0316002A (pt) * 2002-11-06 2005-09-13 Celgene Corp Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
WO2004043378A2 (en) 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CA2506442A1 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
KR20050075435A (ko) * 2002-11-18 2005-07-20 셀진 코포레이션 (＋)-３-(３,４-디메톡시-페닐)-３-(１-옥소-１,３-디히드로-이소인돌-２-일)-프로피온아미드의 사용 방법 및 그를포함하는 조성물
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
CN1726012A (zh) * 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
KR20050088243A (ko) 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
MXPA05007346A (es) * 2003-02-04 2005-09-30 Gumlink As Tableta de goma de mascar comprimida.
WO2004068965A1 (en) * 2003-02-04 2004-08-19 Gumlink A/S Compressed chewing gum tablet
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
ATE550022T1 (de) 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
AU2003218606A1 (en) * 2003-03-13 2004-09-30 Altairnano, Inc. Manufacturing of photocatalytic, antibacterial, selfcleaning and optically non-interfering surfaces on tiles and glazed ceramic products
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
EP1462801A3 (en) * 2003-03-24 2005-01-05 Tepnel Lifecodes Methods for determining the negative control value for multi-analyte assays
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
ATE405170T1 (de) * 2003-05-06 2008-09-15 Gumlink As Methode zur herstellung von kaugummigranulat und komprimierten kaugummiprodukten, sowie ein kaugummigranuliersystem
EP1474995B1 (en) * 2003-05-06 2012-11-14 Gumlink A/S A method for producing chewing gum granules, a gum composition extruder and granulating system, and a chewing gum product
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
DE10326899A1 (de) 2003-06-14 2004-12-30 Beiersdorf Ag Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln
US7605194B2 (en) 2003-06-24 2009-10-20 Ppg Industries Ohio, Inc. Aqueous dispersions of polymer-enclosed particles, related coating compositions and coated substrates
US20080112909A1 (en) * 2003-06-24 2008-05-15 Ppg Industries Ohio, Inc. Compositions for providing color to animate objects and related methods
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
US20050009782A1 (en) * 2003-07-09 2005-01-13 Comper Wayne D. Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
NZ545447A (en) 2003-07-23 2010-03-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
EP1648878B9 (en) 2003-07-24 2011-03-16 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
ES2327684T3 (es) 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
NZ544826A (en) * 2003-07-25 2008-07-31 Warner Chilcott Co Inc A doxycycline metal complex in a solid dosage form
MXPA06001331A (es) * 2003-08-01 2006-05-04 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
SI1664041T1 (sl) 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (enExample) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
EA200600921A1 (ru) 2003-11-06 2006-10-27 Селджин Корпорейшн Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
EP1692128A1 (en) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazole compounds and methods of use thereof as protein kinase inhibitors
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US8591974B2 (en) * 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8389032B2 (en) * 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
AU2003287935B2 (en) * 2003-12-30 2008-02-28 Gumlink A/S Chewing gum comprising biodegradable polymers and having accelerated degradability
CA2549673A1 (en) * 2003-12-30 2005-07-14 Gumlink A/S Compressed biodegradable chewing gum
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
KR101184138B1 (ko) * 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
NZ548215A (en) * 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20060003001A1 (en) * 2004-02-11 2006-01-05 John Devane Chronotherapeutic compositions and methods of their use
WO2005077385A2 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
US20090246288A1 (en) * 2004-02-25 2009-10-01 Pharmaceutical Industry Technology And Development Center Taste-masking oral dosage form and method of preparing the same
TWI335227B (en) 2004-02-25 2011-01-01 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
US20050202051A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical vehicle
DE102004013637A1 (de) * 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20060004037A1 (en) * 2004-03-25 2006-01-05 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
FR2868426B1 (fr) * 2004-04-05 2006-06-02 Rhodia Chimie Sa Composition comprenant un polymere et un compose volatil, et son utilisation pour la liberation controlee du compose volatil
JP2007532641A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーション 脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
CN1968700A (zh) * 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
EP1600210A1 (de) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Beladene Mikrosphären
ATE483455T1 (de) 2004-05-28 2010-10-15 Transform Pharmaceuticals Inc Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
ES2319191T3 (es) 2004-07-06 2009-05-05 Gumlink A/S Pastilla de goma de mascar comprimida.
CA2573341A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for prevention of drug diversion
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006017692A2 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
KR20070038553A (ko) * 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
DK200401195A (da) * 2004-08-06 2004-08-06 Gumlink As Layered chewing gum tablet
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CZ296169B6 (cs) * 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US7820200B2 (en) * 2004-09-09 2010-10-26 Luis Estrada Flores Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment
ATE531367T1 (de) 2004-09-17 2011-11-15 Whitehead Biomedical Inst Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
EP1811992A2 (en) * 2004-10-28 2007-08-01 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20080160099A1 (en) * 2004-11-10 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods For Treating or Preventing a Vascular Disease
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US8101745B2 (en) * 2004-12-16 2012-01-24 The Regents Of The University Of California Lung-targeted drugs
ES2459368T3 (es) 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
WO2006066572A2 (en) * 2004-12-22 2006-06-29 Gumlink A/S Biodegradable chewing gum comprising biodegradable polymer with high glass transition temperature
US20080260900A1 (en) * 2004-12-22 2008-10-23 Gumlink A/S Degradable Polymer for Chewing Gum
ES2327840T3 (es) 2004-12-23 2009-11-04 Gpc Biotech Ag Derivados de acido escuarico con actividad antiproliferativa.
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
WO2006083477A2 (en) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
AU2006208045B2 (en) 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101189000A (zh) * 2005-02-14 2008-05-28 纽罗吉斯克斯公司 Trpv1激动剂的递送装置
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006096544A1 (en) * 2005-03-04 2006-09-14 Altairnano, Inc. Ceramic structures for controlled release of biologically active substances
EP1700824A1 (en) * 2005-03-09 2006-09-13 Degussa AG Granules based on pyrogenically prepared silicon dioxide, method for their preparation and use thereof
WO2006105481A1 (en) * 2005-03-30 2006-10-05 Neurogesx, Inc. Low-concentration capsaicin patch and methods for treating neuropathic pain
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
JP5242375B2 (ja) 2005-04-01 2013-07-24 ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体
BRPI0608917A2 (pt) * 2005-04-12 2017-07-11 Elan Pharma Int Ltd Composição de liberação controlada de antibiótico, e, método para o tratamento de infecção bacteriana
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
BRPI0612448A2 (pt) 2005-05-09 2010-11-23 Foamix Ltd composição espumosa de sacarìdeo
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
US7241805B2 (en) * 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
EP1904046A4 (en) * 2005-07-06 2008-10-01 Sepracor Inc COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
US20090214643A1 (en) * 2005-07-19 2009-08-27 Franklin Amie E Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
CA2620224C (en) 2005-08-24 2015-11-24 Penwest Pharmaceuticals Company Sustained release formulations of nalbuphine
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
CA2822094C (en) 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US20070053983A1 (en) * 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
HK1081802A2 (en) * 2005-09-09 2006-05-19 林子深 Intelligent crossroad
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2007050631A2 (en) * 2005-10-25 2007-05-03 Cima Labs Inc. Dosage form with coated active
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2628031C (en) 2005-11-10 2013-03-05 Circ Pharma Research And Development Limited Once-daily administration of central nervous system drugs
PL1951718T3 (pl) 2005-11-21 2012-08-31 Purdue Pharma Lp Związki 4-oksadiazolilo-piperydyny i ich zastosowanie
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
JP2009516589A (ja) * 2005-11-22 2009-04-23 アルテアナノ インコーポレイテッド 高表面積ナノ多孔性触媒の製造方法および触媒支持構造物
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
WO2007087443A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
JP2009524677A (ja) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
JP2009528273A (ja) 2006-01-25 2009-08-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用の置換ビアリール化合物
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
AU2007211276B2 (en) 2006-01-31 2013-06-06 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
WO2007089883A2 (en) 2006-01-31 2007-08-09 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
AU2007225088B2 (en) 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
WO2007106468A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
BRPI0708879A2 (pt) * 2006-03-13 2011-06-14 Encysive Pharmaceuticals peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
ATE476418T1 (de) * 2006-06-08 2010-08-15 Amgen Inc Benzamidderivate und assoziierte verwendungen
DE602006021637D1 (de) * 2006-06-16 2011-06-09 Gumlink As Kaugummi enthaltend eine hydrophobe enzymformulierung
CA2655904C (en) 2006-06-22 2014-11-18 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
WO2007150001A1 (en) 2006-06-22 2007-12-27 Anadys Pharmaceuticals, Inc. Pyrro[1,2-b]pyridazinone compounds
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
EP2069021A2 (en) * 2006-08-04 2009-06-17 AGI Therapeutics Research Limited Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
US8601530B2 (en) * 2006-09-19 2013-12-03 The Invention Science Fund I, Llc Evaluation systems and methods for coordinating software agents
MX2009002960A (es) 2006-09-21 2009-06-26 Activx Biosciences Inc Inhibidores de serina hidrolasa.
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
WO2008049116A2 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
PT2076268E (pt) 2006-10-19 2013-03-07 Genzyme Corp Roscovitina para o tratamento de certas doenças císticas
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
EP2086326B1 (en) 2006-11-13 2014-01-08 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
CN101611008A (zh) * 2006-12-22 2009-12-23 恩希赛弗制药公司 C3a受体调节剂及其使用方法
CA2673586A1 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
EP2397477B1 (en) 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclic-substituted piperidine compounds and the uses thereof
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2500337A3 (en) 2007-02-21 2012-12-26 Sepracor Inc. Solid form comprising (-) o-desmethylvenlafaxine and uses thereof
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008106166A2 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
CA2680912C (en) 2007-03-15 2017-11-14 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
CA2685121A1 (en) 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2019101A1 (en) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
MX2009012685A (es) 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US8415294B2 (en) * 2007-06-05 2013-04-09 Arizona Board Of Regents Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
EP2173167A4 (en) * 2007-07-06 2010-07-28 Nuon Therapeutics Inc TREATMENT OF NEUROPATHIC PAIN
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
ES2440267T3 (es) 2007-08-01 2014-01-28 Synta Pharmaceuticals Corporation Compuestos de heterociclo-arilo para la inflamación y usos inmunorrelacionados
EP2185514A4 (en) 2007-08-01 2011-05-18 Synta Pharmaceuticals Corp VINYL-ARYL DERIVATIVES FOR INFLAMMATORY AND IMMUNE DISORDERS
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CA2695583A1 (en) 2007-08-13 2009-02-19 Metabasis Therapeutics, Inc. Novel activators of glucokinase
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
WO2009027820A2 (en) 2007-08-31 2009-03-05 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
CA2699151A1 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
KR101597841B1 (ko) 2007-09-12 2016-02-26 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
AU2008305581C1 (en) 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US20090211576A1 (en) * 2007-10-02 2009-08-27 Timo Lehtonen Safety and abuse deterrent improved device
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101343399B1 (ko) 2008-01-08 2013-12-19 퍼듀 퍼머 엘피 통증 치료를 위한 카나비노이드 수용체에 대한 리간드로서의 프롤린 유사체
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
AU2009226136B2 (en) 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
US8815906B2 (en) 2008-03-19 2014-08-26 Chembridge Corporation Tyrosine kinase inhibitors
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
CA2718966A1 (en) * 2008-03-20 2009-09-24 Lynn Chambers Anti-inflammatory drug delivery system
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
RS52590B2 (sr) 2008-07-21 2018-05-31 Purdue Pharma Lp Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
US8530494B2 (en) 2008-07-30 2013-09-10 Purdue Pharma Lp Buprenophine analogs
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2350064A1 (en) * 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010042834A1 (en) 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
CA2957226C (en) 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
AU2009330355B2 (en) 2008-12-16 2016-06-30 Sunovion Pharmaceuticals Inc. Triple reuptake inhibitors and methods of their use
US9056857B2 (en) 2008-12-22 2015-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
US20110306605A1 (en) 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9504274B2 (en) * 2009-01-27 2016-11-29 Frito-Lay North America, Inc. Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom
US20100189845A1 (en) * 2009-01-27 2010-07-29 Frito-Lay North America Inc. Flavor Encapsulation and Method Thereof
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
EP2393357B1 (en) 2009-02-09 2015-08-26 Sunovion Pharmaceuticals Inc. Pyrrolidine triple reuptake inhibitors
MY160002A (en) 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
CA2984935C (en) * 2009-02-24 2021-01-12 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CA2752885A1 (en) 2009-02-27 2010-09-02 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and methods of use thereof
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
CA2755120C (en) * 2009-03-11 2017-05-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
CA2756067A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
AU2010239311B2 (en) 2009-04-20 2014-05-22 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CN102459210B (zh) 2009-04-22 2015-09-02 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
KR101687144B1 (ko) 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
EP2727908A3 (en) 2009-04-22 2014-08-20 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
EP2471518B1 (en) 2009-05-18 2017-08-23 Sigmoid Pharma Limited Composition comprising oil drops
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
KR20120035183A (ko) 2009-06-10 2012-04-13 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
JP5905387B2 (ja) 2009-07-08 2016-04-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ チオ硫酸ナトリウムを含有する薬学的組成物
US20110021591A1 (en) * 2009-07-21 2011-01-27 Gordon Douglas J Phenylbutazone carrier formulation showing increased bioactivity in animals
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
NZ599215A (en) 2009-09-04 2014-11-28 United Paragon Associates Inc Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
JP2013504580A (ja) 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
EP3064064A1 (en) * 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
WO2011042482A1 (en) 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
WO2011046609A2 (en) * 2009-10-15 2011-04-21 Appleton Papers Inc. Encapsulation
RS53716B1 (sr) 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
MX2012004741A (es) 2009-11-19 2012-05-22 Celgene Corp Apremilast para el tratamiento de sarcoidosis.
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
US20110123672A1 (en) * 2009-11-23 2011-05-26 Xiaohu Xia Gum bases, chewing gums based thereupon, and methods for making the same
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
RU2578956C2 (ru) 2009-12-04 2016-03-27 Суновион Фармасьютикалз Инк. Лекарственные формы, соли и полиморфы транснорсертралина и их применение
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
US20110238036A1 (en) * 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
CA2785978A1 (en) 2009-12-30 2011-07-07 Scynexis, Inc. Cyclosporine analogues
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX337566B (es) 2010-01-05 2016-03-10 Celgene Corp Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US8409628B2 (en) * 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
US9120815B2 (en) 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US20110223297A1 (en) * 2010-03-12 2011-09-15 Pepsico., Inc. Anti-Caking Agent for Flavored Products
TWI509247B (zh) * 2010-03-12 2015-11-21 西建公司 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
MX336559B (es) 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida.
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
AU2011237592B2 (en) 2010-04-08 2016-10-27 Emory University Substituted androst-4-ene diones
US20130156755A1 (en) 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
US20130171105A1 (en) 2010-05-24 2013-07-04 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
JP2013528180A (ja) 2010-05-28 2013-07-08 ジーイー・ヘルスケア・リミテッド 放射性標識化合物及びその製造方法
AU2011261501B2 (en) 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
EP2576532B1 (en) 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
WO2012012370A1 (en) 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012025217A1 (en) 2010-08-24 2012-03-01 Algiax Pharmaceuticals Gmbh Novel use of leflunomide and malononitrilamides
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2611789A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US20130225614A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
US8703943B2 (en) 2010-09-01 2014-04-22 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
MX2013002383A (es) 2010-09-01 2013-07-05 Ambit Biosciences Corp Sales bromhidrato de una pirazolilaminoquinazolina.
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
JP2013537229A (ja) 2010-09-13 2013-09-30 シンタ ファーマシューティカルズ コーポレーション 野生型ｅｇｆｒ及び／又はｋｒａｓ患者において非小細胞肺癌を処置するためのｈｓｐ９０阻害剤
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
CN103391784A (zh) 2010-10-15 2013-11-13 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
HRP20171587T1 (hr) 2010-10-18 2017-12-01 Cerenis Therapeutics Holding Sa Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola
BR112013009635A2 (pt) 2010-10-19 2016-07-12 Elcelyx Therapeutics Inc terapias à base de ligante de receptor quimiossensorial
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
HUE034890T2 (hu) 2010-10-29 2018-03-28 Algiax Pharmaceuticals Gmbh Malononitrilaminok alkalmazása neuropathiás fájdalomban
US20130289071A1 (en) 2010-11-09 2013-10-31 Synta Pharmaceuticals Corp. Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US20140005145A1 (en) 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
MX354210B (es) 2010-12-16 2018-02-16 Celgene Corp Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
JP5872585B2 (ja) 2010-12-22 2016-03-01 パーデュー、ファーマ、リミテッド、パートナーシップ リン置換キノキサリンタイプピペリジン化合物とその使用
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
ES2632979T3 (es) 2011-01-10 2017-09-18 Celgene Corporation Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
US20130331357A1 (en) 2011-01-11 2013-12-12 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
RS54447B1 (sr) 2011-01-20 2016-06-30 Bionevia Pharmaceuticals Inc. Modifikovano oslobađajuće kompozicije epalrestata ili njegovih derivata i postupci njihove upotrebe
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
EP2678014A2 (en) 2011-02-24 2014-01-01 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
SI2683384T1 (sl) 2011-03-11 2016-05-31 Celgene Corporation Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
WO2012123406A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of imidazotriazinones
EP2685975A1 (en) 2011-03-17 2014-01-22 Algiax Pharmaceuticals GmbH Novel use of benzofuranylsulfonates
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP2691388A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CA2831590A1 (en) 2011-03-28 2012-10-04 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US20120321590A1 (en) 2011-04-06 2012-12-20 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
ES2661583T3 (es) 2011-04-28 2018-04-02 Celgene Corporation Métodos y composiciones usando inhibidores de PDE4 para el tratamiento y gestión de enfermedades autoinmunes e inflamatorias
MX365710B (es) 2011-04-29 2019-06-11 Intercontinental Great Brands Llc Acido encapsulado, metodo para la preparacion del mismo y goma de mascar que comprende el mismo.
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP2704701B1 (en) 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
EP2704726B1 (en) 2011-05-04 2018-10-31 Trustees of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
KR20140037193A (ko) 2011-06-07 2014-03-26 애나디스 파마슈티칼스, 인코포레이티드 혈청 요산을 낮추기 위한 [1,2,4]티아디아진 1,1-다이옥사이드 화합물
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
EP2744494A1 (en) 2011-08-19 2014-06-25 Synta Pharmaceuticals Corporation Combination cancer therapy of hsp90 inhibitor with antimetabolite
EP2747762B1 (en) 2011-08-23 2015-07-01 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2758067A1 (en) 2011-09-23 2014-07-30 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
EP2760456A1 (en) 2011-09-26 2014-08-06 Celgene Corporation Combination therapy for chemoresistant cancers
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013052776A1 (en) 2011-10-07 2013-04-11 Cedars-Sinai Medical Center Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
KR102066297B1 (ko) 2011-10-14 2020-01-14 암비트 바이오사이언시즈 코포레이션 헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
JP5946921B2 (ja) 2011-12-08 2016-07-06 パーデュー、ファーマ、リミテッド、パートナーシップ 四級化ブプレノルフィン類似体
EP2793580A4 (en) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc NEW DERIVATIVES OF ISO-ERGOLINE
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
HRP20190116T1 (hr) 2012-01-05 2019-03-08 Boston Medical Center Corporation Slit-robo signaliziranje, namijenjeno dijagnosticiranju i liječenju bubrežne bolesti
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
US9085551B2 (en) 2012-02-21 2015-07-21 Celgene Corporation Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2013142114A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP2830616A1 (en) 2012-03-27 2015-02-04 Incuron LLC Curaxins for use in treating breast cancer and method for identifying patients likely to respond
CA2868258A1 (en) 2012-03-28 2013-10-03 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
EP2834227A1 (en) 2012-04-04 2015-02-11 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA3095012C (en) 2012-05-01 2023-02-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US20150099721A1 (en) 2012-05-10 2015-04-09 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013167963A1 (en) 2012-05-11 2013-11-14 Purdue Pharma L.P. Benzomorphan compounds as opioid receptors modulators
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
JP6427097B2 (ja) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌を処置するための組成物および該組成物を製造するための方法
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
JP2015525781A (ja) 2012-07-31 2015-09-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の調節
UA116544C2 (uk) 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
LT2882737T (lt) 2012-08-09 2019-04-25 Celgene Corporation (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
KR20210073616A (ko) 2012-08-09 2021-06-18 셀진 코포레이션 면역-관련 및 염증성 질환의 치료
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
BR112015004959A2 (pt) 2012-09-07 2017-07-04 Axikin Pharmaceuticals Inc composto isotopicamente enriquecido, composição farmacêutica, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença, distúrbio ou condição mediada por ccr3, relacionada a eosinófilos, relacionada a basófilos, relacionada a mastócitos ou relacionada a mastócitos em um sujeito, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença inflamatória em um sujeito e método para modular a atividade de ccr3.
CN104797256A (zh) 2012-09-10 2015-07-22 细胞基因公司 用于治疗局部晚期乳腺癌的方法
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014059251A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2916830A2 (en) 2012-11-08 2015-09-16 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
EP2916869A1 (en) 2012-11-09 2015-09-16 Celgene Corporation Methods for the treatment of bone loss
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US9670230B2 (en) 2012-11-29 2017-06-06 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
WO2014085633A1 (en) 2012-11-30 2014-06-05 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
TW201434842A (zh) 2012-12-07 2014-09-16 Purdue Pharma Lp 丁基原啡因（ｂｕｐｒｅｎｏｒｐｈｉｎｅ）類似物類
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
EP2931726B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Spirocyclic morphinans and their use
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
CA2896202A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
EP2941430B1 (en) 2012-12-28 2017-04-26 Purdue Pharma LP 7,8-cyclicmorphinan analogs
WO2014106238A1 (en) 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
EP2941245B1 (en) 2013-01-05 2024-06-26 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
EP2943593B1 (en) 2013-01-08 2019-04-24 Enzo Biochem, Inc. Diagnosis and treatment of herpesvirus saimiri associated diseases
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
AU2014244053B2 (en) 2013-03-13 2018-08-30 University Of Cincinnati Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist
US9872854B2 (en) 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP2981262A1 (en) 2013-04-02 2016-02-10 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US20160113911A1 (en) 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
EP3881859B1 (en) 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
BR112015031278B1 (pt) 2013-06-14 2022-05-17 Akamara Therapeutics, Inc Compostos e nanopartículas de platina com base em lipídio, seus processos de preparação, composições farmacêuticas compreendendo os mesmos e seus usos no tratamento de câncer
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2014203140A1 (en) 2013-06-22 2014-12-24 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
US20160120861A1 (en) 2013-06-28 2016-05-05 Purdue Pharma L.P. Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
EP3038625A4 (en) 2013-08-29 2017-08-23 Trustees of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
WO2015031613A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3049082B1 (en) 2013-09-24 2019-05-22 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3502270B1 (en) 2013-10-21 2020-03-18 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en) 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
RU2696584C1 (ru) 2013-11-11 2019-08-05 НАТЮРЕКС-ДиБиЭс ЭлЭлСи Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
AU2014364520B2 (en) 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015102682A1 (en) 2013-12-30 2015-07-09 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
EP3096749B1 (en) 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
JP6542791B2 (ja) 2014-03-10 2019-07-10 カドモン コーポレイション，リミティド ライアビリティ カンパニー 脳及び中枢神経系腫瘍の治療
WO2015140081A1 (en) 2014-03-18 2015-09-24 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
IL291000B2 (en) 2014-03-20 2024-04-01 Capella Therapeutics Inc Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CA2943231C (en) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
WO2015153345A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
CA2944549A1 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US20170045528A1 (en) 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
JP6792454B2 (ja) 2014-04-25 2020-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
EP3142748B1 (en) 2014-05-15 2019-09-11 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
EP3142663A1 (en) 2014-05-16 2017-03-22 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US11021435B2 (en) 2014-05-19 2021-06-01 Northeastern University Serotonin receptor-targeting compounds and methods
EP3145500A1 (en) 2014-05-23 2017-03-29 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
JP2017518307A (ja) 2014-06-02 2017-07-06 チルドレンズ メディカル センター コーポレーション 免疫調節のための方法および組成物
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
ES2843973T3 (es) 2014-06-27 2021-07-21 Celgene Corp Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CN106794233B (zh) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2016025686A1 (en) 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US10385343B2 (en) 2014-08-29 2019-08-20 Children's Medical Center Corporation Methods and compositions for the treatment of cancer
AU2015314830B2 (en) 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CA2970358A1 (en) 2014-12-16 2016-06-23 Celgene Corporation Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
CA2976072A1 (en) 2015-02-09 2016-08-18 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
EP4194001B1 (en) 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment of type 2 diabetes and obesity
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3303361A1 (en) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
SI3313818T1 (sl) 2015-06-26 2024-03-29 Celgene Corporation Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
US10570152B2 (en) 2015-07-28 2020-02-25 Vyome Therapeutics Limited Antibacterial therapeutics and prophylactics
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
MX2018002183A (es) 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3355909B1 (en) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
AU2016329201A1 (en) 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3362458A1 (en) 2015-10-16 2018-08-22 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
DK3368534T3 (da) 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3373916A1 (en) 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CN122562777A (zh) 2015-12-02 2026-08-14 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
AU2017250086A1 (en) 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US11497738B2 (en) 2016-04-29 2022-11-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
WO2017192858A1 (en) 2016-05-04 2017-11-09 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
ES2967074T3 (es) 2016-07-18 2024-04-25 Pharmena S A 1 metilnicotinamida para el tratamiento de una enfermedad cardiovascular
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
CN109982687A (zh) 2016-09-19 2019-07-05 梅制药公司 联合疗法
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
EP4112053B1 (en) 2016-10-11 2024-02-14 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Treatment of synucleinopathies
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
CN110088210A (zh) 2016-10-21 2019-08-02 美国大仁医疗有限公司 与酪氨酸激酶抑制剂结合使用的癌细胞增敏剂和增敏方法
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN110167542A (zh) 2016-11-09 2019-08-23 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
TW202515564A (zh) 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JP7062010B2 (ja) 2017-01-27 2022-05-02 セルジーン コーポレイション ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EP3577119B1 (en) 2017-02-06 2025-11-26 Spero Therapeutics, Inc. Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018156609A1 (en) 2017-02-21 2018-08-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
JP7244428B2 (ja) 2017-02-27 2023-03-22 シャタック ラボ，インコーポレイテッド Ｖｓｉｇ８ベースのキメラタンパク質
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
CN110799192A (zh) 2017-03-27 2020-02-14 加利福尼亚大学董事会 治疗癌症的组合物和方法
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
CA3058214A1 (en) 2017-03-29 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University 11,13-modified saxitoxins for the treatment of pain
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン－アニリン化合物
WO2018222831A1 (en) 2017-05-31 2018-12-06 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019005874A1 (en) 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3071854A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
KR20260033622A (ko) 2017-10-04 2026-03-10 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조절성 올리고사카라이드
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019097080A1 (en) 2017-11-20 2019-05-23 Kiakos Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
JP2021506974A (ja) 2017-12-18 2021-02-22 スターングリーン、インク． チロシンキナーゼ阻害剤として有用なピリミジン化合物
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
MX2020007817A (es) 2018-01-24 2020-09-25 Purdue Pharma Lp Prevención y tratamiento del trastorno del sueño.
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
WO2019161236A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
JP7384815B2 (ja) 2018-03-22 2023-11-21 ザ チルドレンズ メディカル センター コーポレーション 肺の修復に関する方法および組成物
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN108836948B (zh) * 2018-06-11 2024-04-12 宁波西敦医药包衣科技有限公司 一种利用包衣技术实现营养素可控制释放的产品
JOP20200298A1 (ar) 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MX2021002292A (es) 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
AU2019372141A1 (en) 2018-11-01 2021-05-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
US20220000976A1 (en) 2018-11-09 2022-01-06 The Children's Medical Center Corporation Methods and compositions for treating or preventing the development of food allergies
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113645964B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
CN113660931B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
WO2020163704A1 (en) 2019-02-07 2020-08-13 Alsatech, Inc. Polyvalent derivatives of emoxypine
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
AU2020231396B2 (en) 2019-03-07 2025-03-20 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
JP2022524887A (ja) 2019-03-22 2022-05-10 ドイチェス クレブスフォルシュングスツェントルム ヒストンデアセチラーゼ１０の新規の阻害剤
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
WO2020205486A1 (en) 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
KR20220004066A (ko) 2019-04-03 2022-01-11 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 약물 전달용 이온성 액체
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2020227437A1 (en) * 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
EP3978076A4 (en) 2019-06-03 2023-02-22 Irimajiri Therapeutics Inc. CYCLIC AMIDE COMPOUNDS FOR THE TREATMENT OF RABIES AND METHODS THEREOF
WO2020257722A2 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
GB201909137D0 (en) * 2019-06-25 2019-08-07 Univ Aston Mesoporous polymeric particulate material
WO2021007478A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
EP3996813A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP4003314B1 (en) 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
MX2022003929A (es) 2019-10-01 2022-06-14 Molecular Skin Therapeutics Inc Compuestos de benzoxazinona como inhibidores dobles de klk5/7.
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
CN114980864A (zh) 2019-11-22 2022-08-30 哈佛大学校长及研究员协会 用于药物递送的离子液体
KR20220110243A (ko) 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법
US20230093147A1 (en) 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
US20230102247A1 (en) 2020-04-28 2023-03-30 President And Fellows Of Harvard College Methods and compositions relating to ionic liquid adjuvants
WO2021226033A1 (en) 2020-05-07 2021-11-11 President And Fellows Of Harvard College Hyaluronic acid drug conjugates
CA3179635A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
CA3180060A1 (en) 2020-05-29 2021-12-02 Zongmin ZHAO Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US20230102840A1 (en) 2020-06-23 2023-03-30 President And Fellows Of Harvard College Compositions and methods relating to combinatorial hyaluronic acid conjugates
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
WO2022008976A1 (en) 2020-07-10 2022-01-13 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
EP4196482B1 (en) 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
US20220133669A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
US12649787B2 (en) 2021-01-15 2026-06-09 President And Fellows Of Harvard College Methods and compositions relating to anti-MFSD2A antibodies
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022187573A1 (en) 2021-03-05 2022-09-09 President And Fellows Of Harvard College Methods and compositions relating to cell membrane hybridization and camouflaging
WO2022189010A1 (en) 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
IL319926A (en) 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4340837A4 (en) 2021-05-21 2025-04-09 Purdue Pharma L.P. METHODS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022265880A1 (en) 2021-06-16 2022-12-22 President And Fellows Of Harvard College Improved methods and compositions for drug delivery relating to ionic liquids
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
KR20240044458A (ko) 2021-08-05 2024-04-04 브리스톨-마이어스 스큅 컴퍼니 Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
WO2023034506A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin
EP4396578A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for promoting adipocyte beiging
WO2023034507A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
EP4396331A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
EP4399278A1 (en) 2021-09-09 2024-07-17 Flagship Pioneering Innovations VI, LLC Methods and compositions for modulating enteroendocrine cells
WO2023039164A2 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
US20240374592A1 (en) 2021-09-14 2024-11-14 Flagship Pioneering Innovations Vi, Llc Methods and compositions for perturbing monocyte and neutrophil lineages
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
JP2024538700A (ja) 2021-10-08 2024-10-23 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
EP4436407A1 (en) 2021-11-22 2024-10-02 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
IL312132A (en) 2021-11-30 2024-06-01 Kura Oncology Inc Macrocyclic compounds having farnesyltransferase inhibitory activity
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4486764A4 (en) 2022-02-28 2026-03-18 Childrens Medical Ct Corp Chimeric antigen receptor regulatory T lymphocytes targeting co-stimulatory molecules to prevent and/or treat inflammatory conditions
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
US12187732B2 (en) 2022-03-28 2025-01-07 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2023245901A1 (en) 2022-03-30 2024-10-03 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
EP4508044A1 (en) 2022-04-14 2025-02-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
CA3256486A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management
EP4519439A1 (en) 2022-05-05 2025-03-12 BioMarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
EP4531879A1 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VI, LLC Compositions of secretory and/or catalytic cells and methods using the same
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
EP4578856A4 (en) 2022-09-30 2026-07-29 Ubience Inc HETEROCYCLIC COMPOUND
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
IL320183A (en) 2022-10-18 2025-06-01 Eluciderm Inc 2-Substituted 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES for wound treatment
EP4608388A1 (en) 2022-10-25 2025-09-03 Starrock Pharma Inc. Combinatorial, and rotational combinatorial therapies for obesity and other diseases
EP4608834A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
EP4608839A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
TW202434251A (zh) 2022-11-04 2024-09-01 美商必治妥美雅史谷比公司 治療癌症之療法
US20260193236A1 (en) 2022-11-30 2026-07-09 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
EP4626865A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
AU2023418987A1 (en) 2022-12-30 2025-07-03 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
AU2024245246A1 (en) 2023-03-27 2025-10-30 Tonix Pharma Limited (s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor
CN121311595A (zh) 2023-04-17 2026-01-09 阿斯克生物公司 转基因在灵长类动物中可调节的受控表达
JP2026516311A (ja) 2023-04-24 2026-05-21 バイオマリン ファーマシューティカル インコーポレイテッド Ｓｔｘｂｐ１障害を治療するための組成物および方法
WO2024233303A1 (en) 2023-05-05 2024-11-14 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
EP4687888A2 (en) 2023-05-16 2026-02-11 Lilac Therapeutics, Inc. Phenol prodrugs
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
CN122003411A (zh) 2023-09-27 2026-05-08 爱索斯特里克斯公司 Myst抑制剂
CN121985956A (zh) 2023-10-09 2026-05-05 奇华顿股份有限公司 组合物
KR20260094777A (ko) 2023-10-16 2026-06-23 브리스톨-마이어스 스큅 컴퍼니 Gspt1 화합물 및 상기 화합물의 사용 방법
IL326884A (en) 2023-10-19 2026-04-01 Purdue Pharma Lp Sunobinop for use in method of treating alcohol use disorder
KR20260100334A (ko) 2023-10-20 2026-06-29 알타이 테라퓨틱스, 인크. 신경근육 장애 등의 치료를 위한 dux4 억제제로서의 n-페닐-3-(2,5-디옥소피롤리딘-1-일)프로판아미드 유도체 및 유사 화합물
WO2025102082A1 (en) 2023-11-10 2025-05-15 Altay Therapeutics, Inc. Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
TW202532072A (zh) 2023-12-08 2025-08-16 美商西建公司 治療多發性骨髓瘤之療法
AU2025206198A1 (en) 2024-01-04 2026-07-23 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
AU2025211735A1 (en) 2024-01-24 2026-07-16 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025221809A1 (en) 2024-04-16 2025-10-23 Eluciderm Inc. 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
TW202604501A (zh) 2024-05-17 2026-02-01 美商賽特溫治療公司 用於治療疼痛之ＮＡｖ１．８之經取代之環烷基及雜環烷基抑制劑
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
WO2026068775A1 (en) 2024-09-27 2026-04-02 Tonix Pharma Limited (s)-tianeptine and use in treating post-concussive syndrome, nociplastic pain syndrome and chronic overlapping pain conditions
WO2026099206A1 (en) 2024-11-05 2026-05-15 Celgene Corporation Therapy for the treatment of non-hodgkin lymphoma
WO2026120283A1 (en) 2024-12-06 2026-06-11 Celgene Corporation Assessing subjects having acute st-elevation myocardial infarctions

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA873815A (en) * 1971-06-22 G. Mason Stanley Encapsulated hydrophilic compositions and methods of making them
CA494130A (en) * 1953-06-30 Western Electric Company, Incorporated Power and impedance monitor
NL6603111A (enExample) * 1956-11-24 1966-09-20
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3115441A (en) * 1962-06-06 1963-12-24 Victor M Hermelin Timed release pharmaceutical preparations and method of making the same
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
US3341416A (en) * 1963-12-11 1967-09-12 Ncr Co Encapsulation of aspirin in ethylcellulose and its product
GB1056259A (en) * 1964-11-30 1967-01-25 Lyons & Co Ltd J Flavour powders
US3594326A (en) * 1964-12-03 1971-07-20 Ncr Co Method of making microscopic capsules
US3460972A (en) * 1965-09-29 1969-08-12 Battelle Development Corp Liquid encapsulation
US3488418A (en) * 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
GB1205770A (en) * 1966-07-26 1970-09-16 Nat Patent Dev Corp Body implants
AT270071B (de) * 1966-08-12 1969-04-10 Roehm & Haas Gmbh Dragierlack für Arzneiformen
US3657144A (en) * 1967-06-05 1972-04-18 Ncr Co Encapsulation process
US3594470A (en) * 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
US3732172A (en) * 1968-02-28 1973-05-08 Ncr Co Process for making minute capsules and prefabricated system useful therein
US3576759A (en) * 1968-04-12 1971-04-27 Ncr Co Process for en masse production of spherules by desiccation
JPS5212150B1 (enExample) * 1968-06-04 1977-04-05
US3639306A (en) * 1968-08-08 1972-02-01 Amicon Corp Encapsulating particles and process for making same
US3539465A (en) * 1968-10-08 1970-11-10 Ncr Co Encapsulation of hydrophilic liquid-in-oil emulsions
US3634586A (en) * 1968-12-04 1972-01-11 Bristol Myers Co Stable aqueous suspensions of ampicillin
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3567650A (en) * 1969-02-14 1971-03-02 Ncr Co Method of making microscopic capsules
US3642978A (en) * 1969-03-05 1972-02-15 Mochida Pharm Co Ltd Process for producing stable cytochrome c preparation
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
GB1287431A (en) * 1969-04-16 1972-08-31 Aspro Nicholas Ltd Improvements in pharmaceutical formulations
US3703576A (en) * 1969-08-08 1972-11-21 Fuji Photo Film Co Ltd Method of producing micro-capsules enclosing acetylsalicylic acid therein
US3629392A (en) * 1969-08-15 1971-12-21 Gilbert S Banker Entrapment compositions and processes
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
CA923384A (en) * 1970-02-03 1973-03-27 Abe Jinnosuke Process for preparing a micro capsule
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1359643A (en) * 1970-09-28 1974-07-10 Controlled Medications Controlled release medicament
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US3821422A (en) * 1971-03-04 1974-06-28 Merck & Co Inc Devil's food cake and other alkaline bakery goods
JPS5214234B2 (enExample) * 1971-07-30 1977-04-20
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
JPS528795B2 (enExample) * 1971-12-30 1977-03-11
JPS523342B2 (enExample) * 1972-01-26 1977-01-27
GB1403584A (en) * 1972-05-19 1975-08-28 Beecham Group Ltd Control medicaments
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS5438164B2 (enExample) * 1972-05-29 1979-11-19
BE791458A (fr) * 1972-07-31 1973-05-16 Merck & Co Inc Produit microencapsule
DE2237503A1 (de) * 1972-07-31 1974-10-03 Basf Ag Verfahren zur herstellung von mikrokapseln
JPS4962623A (enExample) * 1972-10-18 1974-06-18
JPS4993522A (enExample) * 1973-01-12 1974-09-05
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
FR2236483B1 (enExample) * 1973-07-12 1976-11-12 Choay Sa
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS5094112A (enExample) * 1973-12-06 1975-07-26
US3962468A (en) * 1974-03-07 1976-06-08 General Foods Corporation Spray-dried L-aspartic acid derivatives
US4118336A (en) * 1974-03-25 1978-10-03 Toyo Jozo Company, Ltd. Novel cellulose microcapsules and preparation thereof
DE2452975C2 (de) * 1974-11-08 1982-09-16 Dr. C. Otto & Comp. Gmbh, 4630 Bochum Füllwagen für Verkokungsöfen
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4123381A (en) * 1975-02-20 1978-10-31 Toyo Jozo Company, Ltd. Process for producing cellulose microcapsules, and resulting cellulose microcapsules
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
JPS523653A (en) * 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US4324683A (en) * 1975-08-20 1982-04-13 Damon Corporation Encapsulation of labile biological material
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
PT66201B (fr) * 1976-02-23 1978-11-07 Corvi Mora E Procede et composition pour la therapeutique des maladies circulatoires cerebrales
CH627449A5 (de) * 1977-03-25 1982-01-15 Hoffmann La Roche Verfahren zur herstellung von mikrokristallinem vitamin a-acetat, sowie von trockenen, frei-fliessenden praeparaten, in welchen vitamin a-acetat in mikrokristalliner form vorliegt.
WO1978000011A1 (fr) * 1977-06-07 1978-12-21 Garching Instrumente Forme d'implant medicamenteux et procede de preparation
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
AT355053B (de) * 1978-03-03 1980-02-11 Koreska Gmbh W Mikrokapseln fuer aufzeichnungsmaterialien und verfahren zu deren herstellung
DE2809659A1 (de) * 1978-03-07 1979-09-13 Kores Holding Zug Ag Mikrokapseln fuer aufzeichnungsmaterialien und verfahren zu deren herstellung
US4182778A (en) * 1978-05-17 1980-01-08 General Foods Corporation Encapsulation of vitamin and mineral nutrients
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
US4489055A (en) * 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
JPS5524938A (en) * 1978-08-10 1980-02-22 Nippon Kokan Kk <Nkk> Manufacture of galvanized cold rolled steel plate excellent in deep drawability
US4205060A (en) * 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4368197A (en) * 1979-02-21 1983-01-11 Research Corporation Zinc aminophylline and its use in the treatment of bronchospasms
US4201822A (en) * 1979-06-13 1980-05-06 The United States Of America As Represented By The Secretary Of The Army Novel fabric containing microcapsules of chemical decontaminants encapsulated within semipermeable polymers
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
JPS5569509A (en) * 1979-11-30 1980-05-26 Mcleod Patrick Biologically decomposable particle
US4280995A (en) * 1979-12-31 1981-07-28 Pharmaceutical Associates, Inc. Oral suspension of phenytoin
JPS56152739A (en) * 1980-04-25 1981-11-26 Tanabe Seiyaku Co Ltd Production of microcapsule
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
FR2485370A1 (fr) * 1980-06-30 1981-12-31 Commissariat Energie Atomique Support inerte en copolymere reticule, son procede de preparation et son utilisation pour la realisation de medicaments retard
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
JPS58401A (ja) * 1981-06-26 1983-01-05 Yokohama Rubber Co Ltd:The 充填タイヤ
WO1983000284A1 (en) * 1981-07-15 1983-02-03 Key Pharma Sustained release theophylline
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4452821A (en) * 1981-12-18 1984-06-05 Gerhard Gergely Confectionery product, particularly chewing gum, and process for its manufacture
DE3218150C2 (de) * 1982-05-14 1986-09-25 Akzo Gmbh, 5600 Wuppertal Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US4497832A (en) * 1983-04-18 1985-02-05 Warner-Lambert Company Chewing gum composition having enhanced flavor-sweetness
US4590825A (en) 1983-05-06 1986-05-27 John Vaughn High torque fastener and driving tool
GB2141023B (en) * 1983-06-06 1986-09-03 Robins Co Inc A H Delayed release formulations
US4647459A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Confectionery compositions containing magnesium trisilicate adsorbates
US4647450A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Chewing gum compositions containing magnesium trisilicate absorbates
US4632822A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antiasmatics
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
SE8404808L (sv) * 1983-10-03 1985-04-04 Avner Rotman Mikrokapslat lekemedel i sot matris
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
JPS6110A (ja) * 1984-06-08 1986-01-06 Sekisui Chem Co Ltd 貼付製剤の製造方法
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4690825A (en) * 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions

Also Published As

Publication number Publication date
NL193582B (nl) 1999-11-01
DE3538429A1 (de) 1986-04-30
DK495585A (da) 1986-05-01
JP2820239B2 (ja) 1998-11-05
FR2572282B1 (fr) 1989-03-31
AU4916185A (en) 1986-05-08
ZA858300B (en) 1986-07-30
DK175329B1 (da) 2004-08-23
US5354556A (en) 1994-10-11
SE8505099L (sv) 1986-05-01
HK44091A (en) 1991-06-14
DK495585D0 (da) 1985-10-29
FR2572282A1 (fr) 1986-05-02
US4940588A (en) 1990-07-10
US4952402A (en) 1990-08-28
IT8567913A0 (it) 1985-10-29
NL8502951A (nl) 1986-05-16
DE3538429C2 (de) 1996-10-24
SE8505099D0 (sv) 1985-10-29
IT1185831B (it) 1987-11-18
NL193582C (nl) 2000-03-02
BE903540A (fr) 1986-02-17
GB2166651B (en) 1988-11-16
JPS61109711A (ja) 1986-05-28
AU579415B2 (en) 1988-11-24
CA1268051A (en) 1990-04-24
GB2166651A (en) 1986-05-14
GB8526591D0 (en) 1985-12-04
IE58110B1 (en) 1993-07-14
CH669728A5 (enExample) 1989-04-14

Similar Documents

Publication Publication Date Title
RU94042251A (ru) Способ удаления элементарной серы, присутствующей в газе
FR2378720A1 (fr) Procede de preparation de carbonate de calcium precipite
CA2229207A1 (en) Recovery of caprolactam from nylon-6 scrap
FR2506779A1 (fr) Procede et appareil pour la fabrication de matiere carbonee cristallisable
JPS5887102A (ja) 凝固ラテツクスの製造方法および装置
FR2587628B1 (fr) Procede pour la production d&#39;une suspension de particules d&#39;eau ultrafines dans l&#39;air
FR2749310B1 (fr) Procede pour produire des particules de latex polymere coagulees
JPS6037129B2 (ja) 樹脂状重合体から未反応単量体の除去および回収法
DE59202892D1 (de) Verfahren und Anlage zur Aufbereitung von Abfallflüssigkeiten, insbesondere von Industrieabwasser mit hohem Feststoffgehalt.
FR2608961B1 (fr) Procede pour la fabrication d&#39;articles de forme a partir de matieres en particules vegetales
FR2435988A1 (fr) Procede et installation de fabrication de poudre metallique a partir d&#39;un metal ou alliage en fusion
US4110491A (en) Method and apparatus for encapsulating and coagulating elastomers
JPS5630403A (en) Preparation of coagulated latex
BE902521A (fr) Procede de production de particules preexpansees.
JPS5695905A (en) Preparation of coagulated latex
FR2419757A1 (fr) Procede d&#39;agglomeration et appareil pour sa mise en oeuvre
GB2159760A (en) Production of plastics film and sheet
CN217661982U (zh) 一种污泥用mvr蒸发器搅拌装置
FR2590498B1 (fr) Procede pour produire en continu du soufre sous forme de particules solides sensiblement spheriques, individuelles et/ou agglomerees
FR2570959B1 (fr) Procede et installation de fabrication de gouttelettes essentiellement spheriques de dimension approximativement uniforme et de diametre superieur a au moins environ deux millimetres a partir d&#39;un materiau susceptible de s&#39;ecouler, solidifiable, coagulable ou gelifiable contenant de preference des particules en particulier formees par des levures ou microorganismes de fermentation
FR2404517A1 (fr) Procede pour la fabrication de produits bruts en forme de plaque pour realiser des pieces faconnees
FR2397429A1 (fr) Procede pour purifier des gaz de recirculation de particules condensees de polymere
GB1425210A (en) Heat exchanger employing condensation
BE900851A (fr) Procede pour la production constante de particules d&#39;eau.
DE2734946A1 (de) Verfahren und vorrichtung zum entfernen von fluechtigen anteilen, die bei der extrusion von kunststoffschmelzen aus diesen entweichen

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: KANEGAFUCHI KAGAKU KOGYO K.K.

Effective date: 19941031